ECKERT+ZIEGLERINH O.N. overview

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum 30.05.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. BOSTON, Mass., 30 May 2025. Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event...

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time 23.05.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, May 23, 2025. Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI),...

EQS-News: Eckert & Ziegler SE / Key word(s): Quarter Results Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast 13.05.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. 1st Quarter 2025: Sales of € 68.2 million (previous year: € 67.6 million) EBIT before special items of € 16.2 million (previous year: € 15.0 million) Net income of 9.7 Mio. € (previous year: € 8.5 million) Forecast 2025: Sales of around €...

EQS-News: Eckert & Ziegler SE / Key word(s): Agreement/Incoming Orders Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm 24.04.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 24 April 2025. Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical...

EQS-News: Eckert & Ziegler SE / Key word(s): Dividend Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024 11.04.2025 / 10:30 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 11 April 2025. The Supervisory Board of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) approved the Executive Board's resolution to propose a dividend of € 0.50 per share entitled to a dividend for the 2024 financial year at the Annual General Meeting to be held on June 18,...

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig 10.04.2025 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 10 April 2025. US Consul General Jason Chue today visited the Eckert & Ziegler production site in Braunschweig and gained an impression of the production of radiopharmaceuticals for cancer diagnostics and therapy. Eckert & Ziegler maintains a...

EQS-News: Eckert & Ziegler SE / Key word(s): Annual Results/Forecast Eckert & Ziegler: Record year 2024 with new all-time highs 27.03.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50...

EQS-News: Eckert & Ziegler SE / Key word(s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With...